European Commission

#European Commission #Neuroscience #Otsuka #Schizophrenia

EU approves long-acting injectable for schizophrenia

Abilify Maintena 960mg (aripiprazole) has been approved in the EU as the first once-every- two-months long-acting injectable for the maintenance treatment of schizophrenia. The new long-acting injectable (LAI) formulation enables continuous exposure to medication for two months. Aripiprazole once-every-two-months LAI is a new formulation containing 960mg aripiprazole provided in a… Read More

#News #Regulatory

Woman suffering from hot flushes
#Astellas Pharma #European Commission #Menopause #MHRA #Women's health

Novel hot flushes treatment approved in UK and EU

Astellas’ Veoza (fezolinetant) will soon be available to some women in the UK suffering from vasomotor symptoms (VMS) associated with menopause following approval by the Medicines and Healthcare Regulatory Agency (MHRA). Despite VMS, or hot flushes, being a common symptom of menopause, until now, hormone replacement therapy (HRT) was the… Read More

#Editor's Choice #News #Regulatory

Mother helps child to use a nebuliser
#Cystic fibrosis #European Commission #Gene mutation #Genetics / genomics #Paediatrics #Vertex

EU extends paediatric use of combination in cystic fibrosis

A label expansion for Kaftrio (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) has been approved in the European Union (EU). The European Commission has extended use of the therapy to include children with CF aged two through five years old who have at… Read More

#News #Regulatory

#Ascendis Pharma #Chronic hypoparathyroidism #European Commission

EC grants marketing authorisation for chronic hypoparathyroidism drug 

The European Commission (EC) has granted marketing authorisation for YORVIPATH (palopegteriparatide) as replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism.   YORVIPATH is Ascendis Pharma's prodrug of parathyroid hormone (PTH 1-34), administered once daily. Ascendis plans its first EU launch of YORVIPATH in January 2024 in Germany.  “Each… Read More

#News #Regulatory

Stamp of approval
#Chemotherapy #European Commission #Leukaemia #Oncology #Otsuka

European Commission approves oral treatment for leukaemia

The European Commission (EC) has approved INAQOVI (oral decitabine and cedazuridine) as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy. INAQOVI, developed by Otsuka Pharmaceutical and Astex Pharmaceuticals, is the first oral hypomethylating agent to be licensed… Read More

#News #Regulatory

European Commission
#Chemotherapy #European Commission #Jazz Pharmaceuticals #Leukaemia #Paediatrics

EC approves Erwinia-derived asparaginase for leukaemia

The European Commission (EC) has granted marketing authorisation for Jazz Pharmaceuticals’ Enrylaze as part of a multi-agent regimen for acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL). The treatment is approved in adult and paediatric patients who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase. Enrylaze, approved as Rylaze… Read More

#News #Regulatory

European Commission
#Bispecific Antibodies #EU #European Commission #Janssen #Myeloma #Oncology

“Important new approach” to myeloma now available in the EU

The European Commission (EC) has granted conditional marketing authorisation (CMA) for Janssen’s Talvey (talquetamab) as monotherapy for relapsed and refractory multiple myeloma (RRMM). It is approved in adult patients who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have… Read More

#News #Regulatory

#Brexit #European Commission #European Medicines Agency #MHRA #Regulatory #UK #UK budget

Two part commentary on Brexit and drug discovery

On 31 January 2020, the United Kingdom (UK) withdrew from the European Union (EU). Alongside a number of repercussions, the most impactful to the drug discovery sector arguably relates to regulatory affairs on account of adjusting from the European Medicines Agency (EMA) to the Medicines and Healthcare products Regulatory… Read More

#News

#Brexit #European Commission #European Medicines Agency #MHRA #Regulatory #UK #UK budget

Part 1: What impact has Brexit had on UK drug discovery?

On 31 January 2020, the United Kingdom (UK) withdrew from the European Union (EU). Alongside a number of repercussions, the most impactful to the drug discovery sector arguably relates to regulatory affairs on account of adjusting from the European Medicines Agency (EMA) to the Medicines and Healthcare products Regulatory Agency… Read More

#Exclusive Content #Regulatory

#Brexit #European Commission #European Medicines Agency #MHRA #Regulatory #UK #UK bidget

Part 2: What impact has Brexit had on UK drug discovery?

On 31 January 2020, the United Kingdom (UK) withdrew from the European Union (EU). Alongside a number of repercussions, the most impactful to the drug discovery sector arguably relates to regulatory affairs on account of adjusting from the European Medicines Agency (EMA) to the Medicines and Healthcare products Regulatory Agency… Read More

#Exclusive Content #Regulatory

Leukaemia
#Blood cancer #Cancer research #CHMP #EMA #European Commission #Jazz Pharmaceuticals #Leukaemia #Oncology

EU positive opinion for acute lymphoblastic leukaemia drug

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorisation of JZP458 (a recombinant Erwinia asparaginase or crisantaspase). It has been recommended for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic… Read More

#News #Regulatory

CAR-T therapy
#CAR-T #European Commission #European Medicines Agency #Janssen #Myeloma #Oncology #Phase III trial

Janssen seeks EU approval of new indication for CAR-T therapy

The Janssen Pharmaceutical Companies of Johnson & Johnson have submitted a Type II variation application to the European Medicines Agency (EMA) seeking approval of Carvykti (ciltacabtagene autoleucel; cilta-cel) for relapsed and lenalidomide-refractory multiple myeloma. The application is supported by data from the Phase III CARTITUDE-4 study, which evaluated the safety… Read More

#News #Regulatory

EU flag
#Alliance for Regenerative Medicine #EFPIA #EU #European Commission #European Medicines Agency #Regulatory #The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

Proposals for changes to EU pharma legislation raise concerns for SMEs

DDW's Diana Spencer explores the European Commission's proposed changes to EU pharmaceutical legislation, the reaction from industry and possible impact on smaller companies. The European Commission (EC) has proposed the largest reform to the EU's pharmaceutical legislation in over 20 years. The EC says the revisions will make the system more agile, flexible,… Read More

#Exclusive Content #Regulatory

European Commission
#Cancer research #European Commission #Janssen #Oncology #Phase III trial #Prostate cancer

EU approval for dual action prostate cancer therapy

The European Commission (EC) has granted marketing authorisation for Akeega (niraparib and abiraterone acetate [AA]) for adults with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic). The drug is given in the form of a dual action tablet (DAT), with prednisone or prednisolone, and is approved in… Read More

#News #Regulatory

European Commission
#Biosimilars #Comment #European Commission #Opinion #Pharma #Regulatory

European Commission vs Big Pharma, or profit vs access?  

On January 31 2023, an internally circulated version of the European Commission’s overhaul of the EU’s pharma legislation was leaked, and published by Politico1. Politico published a summary of the key propositions outlined in the draft2, and DDW’s Multimedia Editor Megan Thomas investigates their intention, and observes how the industry… Read More

#Exclusive Content #Opinion #Regulatory

The Backstop solution for the Irish border
#Association of the British Pharmaceutical Industry #European Commission #Northern Ireland #Pharmaceutical industry #UK government

Windsor Framework addresses drug supply issues in NI

The European Commission and the UK Government have reached a political agreement that they hope will address the challenges faced by citizens and businesses in Northern Ireland (NI) following Brexit. The Windsor Framework, which focuses on a variety of issues, including supply of medicines, constitutes a comprehensive set of joint… Read More

#News #Trending News